Other Mutations: KK-LC-1

NCT05035407: T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

NCT05035407
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KK-LC-1, HLA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Chemotherapy, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with 3 or fewer brain metastases treated with surgery or stereotactic radiosurgery are eligible; Brian lesions treated with stereotactic radiosurgery must be clinically stable for one month before protocol treatment; Patients with surgically resected brain metastases are eligible
Exclusions: Patients who have not received prior first line standard therapy; Patients with 4 or more brain metastases
https://ClinicalTrials.gov/show/NCT05035407

Up ↑